GlassScriptPhysician profile
Tina Wang
NPI 1700170743
$2,159.21
in general payments reported to CMS, 2019-2025
29 companies · $70.17 in 2025
The $70.17 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $367 · 2021: $392 · 2022: $58.42 · 2023: $105 · 2024: $181 · 2025: $70.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $380.00 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $243.47 | 2019-2021 | |
| Astellas Pharma US INC | $151.84 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $147.39 | 2019-2021 | |
| Btg International INC. | $120.42 | 2024 | |
| Pfizer INC. | $109.82 | 2019-2020 | |
| Seagen INC. | $105.06 | 2023 | Adcetris |
| Janssen Biotech, INC. | $79.27 | 2019-2021 | |
| Pharmaessentia USA Corporation | $70.17 | 2025 | Besremi |
| Morphosys, US INC. | $65.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.20 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $57.63 | 2019-2020 | |
| Glaxosmithkline, LLC. | $44.58 | 2024 | Jemperli, Zejula |
| Celgene Corporation | $41.77 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $40.94 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.76 | 2020-2022 | |
| Tesaro, INC. | $31.89 | 2019 | |
| Incyte Corporation | $24.99 | 2021 | |
| Myovant Sciences INC. | $24.69 | 2021 | |
| Blueprint Medicines Corporation | $24.13 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.69 | 2019 | |
| Genzyme Corporation | $20.93 | 2019 | |
| Exelixis INC. | $20.15 | 2019 | |
| Eisai INC. | $16.67 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.98 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Rigel Pharmaceuticals, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.